Literature DB >> 24187139

Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain.

Leeann J Boerma1, Gang Xia, Cheng Qui, Bryan D Cox, Michael J Chalmers, Craig D Smith, Susan Lobo-Ruppert, Patrick R Griffin, Donald D Muccio, Matthew B Renfrow.   

Abstract

Retinoid X receptors (RXRs) are obligate partners for several other nuclear receptors, and they play a key role in several signaling processes. Despite being a promiscuous heterodimer partner, this nuclear receptor is a target of therapeutic intervention through activation using selective RXR agonists (rexinoids). Agonist binding to RXR initiates a large conformational change in the receptor that allows for coactivator recruitment to its surface and enhanced transcription. Here we reveal the structural and dynamical changes produced when a coactivator peptide binds to the human RXRα ligand binding domain containing two clinically relevant rexinoids, Targretin and 9-cis-UAB30. Our results show that the structural changes are very similar for each rexinoid and similar to those for the pan-agonist 9-cis-retinoic acid. The four structural changes involve key residues on helix 3, helix 4, and helix 11 that move from a solvent-exposed environment to one that interacts extensively with helix 12. Hydrogen-deuterium exchange mass spectrometry reveals that the dynamics of helices 3, 11, and 12 are significantly decreased when the two rexinoids are bound to the receptor. When the pan-agonist 9-cis-retinoic acid is bound to the receptor, only the dynamics of helices 3 and 11 are reduced. The four structural changes are conserved in all x-ray structures of the RXR ligand-binding domain in the presence of agonist and coactivator peptide. They serve as hallmarks for how RXR changes conformation and dynamics in the presence of agonist and coactivator to initiate signaling.

Entities:  

Keywords:  9-cis-UAB30; Agonists; Nuclear Receptors; Protein Dynamics; RXR Receptor; Retinoid; Structural Biology; Targretin; X-ray Crystallography

Mesh:

Substances:

Year:  2013        PMID: 24187139      PMCID: PMC3887207          DOI: 10.1074/jbc.M113.476861

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  65 in total

Review 1.  A structural view of nuclear hormone receptor: endocrine disruptor interactions.

Authors:  Albane le Maire; William Bourguet; Patrick Balaguer
Journal:  Cell Mol Life Sci       Date:  2010-01-09       Impact factor: 9.261

2.  Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid.

Authors:  J P Renaud; N Rochel; M Ruff; V Vivat; P Chambon; H Gronemeyer; D Moras
Journal:  Nature       Date:  1995-12-14       Impact factor: 49.962

3.  A conformational switch in nuclear hormone receptors is involved in coupling hormone binding to corepressor release.

Authors:  B C Lin; S H Hong; S Krig; S M Yoh; M L Privalsky
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

4.  Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene).

Authors:  Peter T Vedell; Yan Lu; Clinton J Grubbs; Yuxin Yin; Hui Jiang; Kirby I Bland; Donald D Muccio; Dusica Cvetkovic; Ming You; Ronald Lubet
Journal:  Mol Pharmacol       Date:  2013-01-04       Impact factor: 4.436

5.  Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.

Authors:  E D Bischoff; M M Gottardis; T E Moon; R A Heyman; W W Lamph
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

6.  Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia.

Authors:  K Wade Foster; Zhaoli Liu; Clinton D Nail; Xingnan Li; Thomas J Fitzgerald; Sarah K Bailey; Andra R Frost; Iuri D Louro; Tim M Townes; Andrew J Paterson; Jeffrey E Kudlow; Susan M Lobo-Ruppert; J Michael Ruppert
Journal:  Oncogene       Date:  2005-02-24       Impact factor: 9.867

7.  Retinoids selective for retinoid X receptor response pathways.

Authors:  J M Lehmann; L Jong; A Fanjul; J F Cameron; X P Lu; P Haefner; M I Dawson; M Pfahl
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

8.  Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism.

Authors:  E A Allegretto; M R McClurg; S B Lazarchik; D L Clemm; S A Kerner; M G Elgort; M F Boehm; S K White; J W Pike; R A Heyman
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

9.  Dynamics and ligand-induced solvent accessibility changes in human retinoid X receptor homodimer determined by hydrogen deuterium exchange and mass spectrometry.

Authors:  Xuguang Yan; David Broderick; Mark E Leid; Michael I Schimerlik; Max L Deinzer
Journal:  Biochemistry       Date:  2004-02-03       Impact factor: 3.162

10.  9-cis retinoic acid is a high affinity ligand for the retinoid X receptor.

Authors:  R A Heyman; D J Mangelsdorf; J A Dyck; R B Stein; G Eichele; R M Evans; C Thaller
Journal:  Cell       Date:  1992-01-24       Impact factor: 41.582

View more
  13 in total

1.  Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.

Authors:  Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

2.  A novel gene expression analytics-based approach to structure aided design of rexinoids for development as next-generation cancer therapeutics.

Authors:  Bentley J Hanish; Jennifer F Hackney Price; Ichiro Kaneko; Ning Ma; Arjan van der Vaart; Carl E Wagner; Peter W Jurutka; Pamela A Marshall
Journal:  Steroids       Date:  2018-04-26       Impact factor: 2.668

3.  Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.

Authors:  Anil Desphande; Gang Xia; LeeAnn J Boerma; Kimberly K Vines; Venkatram R Atigadda; Susan Lobo-Ruppert; Clinton J Grubbs; Fariba L Moeinpour; Craig D Smith; Konstantin Christov; Wayne J Brouillette; Donald D Muccio
Journal:  Bioorg Med Chem       Date:  2013-12-01       Impact factor: 3.641

4.  Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers.

Authors:  Venkatram R Atigadda; Gang Xia; Anil Deshpande; Lizhi Wu; Natalia Kedishvili; Craig D Smith; Helen Krontiras; Kirby I Bland; Clinton J Grubbs; Wayne J Brouillette; Donald D Muccio
Journal:  J Med Chem       Date:  2015-09-22       Impact factor: 7.446

5.  Neuroprotective effect of naturally occurring RXR agonists isolated from Sophora tonkinensis Gagnep. on amyloid-β-induced cytotoxicity in PC12 cells.

Authors:  Wei Wang; Ken-Ichi Nakashima; Takao Hirai; Makoto Inoue
Journal:  J Nat Med       Date:  2018-10-30       Impact factor: 2.343

6.  A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers.

Authors:  Jill M Kolesar; Shannon Andrews; Heather Green; Tom C Havighurst; Barbara W Wollmer; Katina DeShong; Douglas E Laux; Helen Krontiras; Donald D Muccio; KyungMann Kim; Clinton J Grubbs; Margaret G House; Howard L Parnes; Brandy M Heckman-Stoddard; Howard H Bailey
Journal:  Cancer Prev Res (Phila)       Date:  2019-09-04

Review 7.  Applications of hydrogen/deuterium exchange MS from 2012 to 2014.

Authors:  Gregory F Pirrone; Roxana E Iacob; John R Engen
Journal:  Anal Chem       Date:  2014-11-14       Impact factor: 6.986

8.  A molecular switch regulating transcriptional repression and activation of PPARγ.

Authors:  Jinsai Shang; Sarah A Mosure; Jie Zheng; Richard Brust; Jared Bass; Ashley Nichols; Laura A Solt; Patrick R Griffin; Douglas J Kojetin
Journal:  Nat Commun       Date:  2020-02-19       Impact factor: 14.919

9.  Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.

Authors:  Venkatram R Atigadda; Gang Xia; Anil Desphande; LeeAnn J Boerma; Susan Lobo-Ruppert; Clinton J Grubbs; Craig D Smith; Wayne J Brouillette; Donald D Muccio
Journal:  J Med Chem       Date:  2014-06-05       Impact factor: 7.446

10.  Retinoid X Receptor Agonists Upregulate Genes Responsible for the Biosynthesis of All-Trans-Retinoic Acid in Human Epidermis.

Authors:  Lizhi Wu; Sandeep C Chaudhary; Venkatram R Atigadda; Olga V Belyaeva; Steven R Harville; Craig A Elmets; Donald D Muccio; Mohammad Athar; Natalia Y Kedishvili
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.